Cytokinetics, Inc. is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.
The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility. In parallel, Cytokinetics has advanced reldesemtiv, a skeletal muscle activator, into clinical development for neuromuscular disorders such as amyotrophic lateral sclerosis and spinal muscular atrophy. A third key program, apitegromab, seeks to preserve and restore muscle function in patients with muscle‐wasting diseases by inhibiting myostatin activation. Beyond these lead assets, Cytokinetics maintains a pipeline of early‐stage candidates targeting both cardiac and skeletal muscle biology.
While based in the United States, Cytokinetics conducts clinical trials across North America, Europe and Asia, and has forged strategic collaborations with major biopharmaceutical firms to support global development and commercialization. Led by a management team with extensive experience in drug discovery, clinical development and regulatory affairs, the company continues to expand its scientific platform and pursue strategic partnerships. Through its targeted approach to muscle biology, Cytokinetics seeks to bring new therapeutic options to patients suffering from debilitating cardiac and neuromuscular diseases.
AI Generated. May Contain Errors.
Free CYTK Stock Alerts